Should I buy or sell Eagle Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EGRX shares. View EGRX analyst ratings or view top-rated stocks .

What is Eagle Pharmaceuticals' stock price target for 2024?

1 brokerages have issued 12 month price objectives for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they predict the company's share price to reach $17.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View analysts price targets for EGRX or view top-rated stocks among Wall Street analysts .

How have EGRX shares performed in 2023?

Eagle Pharmaceuticals' stock was trading at $29.23 at the start of the year. Since then, EGRX shares have decreased by 79.6% and is now trading at $5.95. View the best growth stocks for 2023 here .

When is Eagle Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023. View our EGRX earnings forecast .

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 6.48% and a net margin of 6.04%. During the same quarter in the previous year, the business earned $0.51 earnings per share.

What guidance has Eagle Pharmaceuticals issued on next quarter's earnings?

Eagle Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share (EPS) guidance of $4.40-$4.70 for the period, compared to the consensus estimate of $4.58. The company issued revenue guidance of -.

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD) , Exelixis (EXEL) , Teekay Tankers (TNK) , AbbVie (ABBV) , Intercept Pharmaceuticals (ICPT) , Schnitzer Steel Industries (RDUS) , bluebird bio (BLUE) , Clovis Oncology (CLVS) , GW Pharmaceuticals (GWPH) and Incyte (INCY) .

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (8.73%), Adage Capital Partners GP L.L.C. (3.85%), AQR Capital Management LLC (2.18%), Smith Graham & Co. Investment Advisors LP (2.10%), Ameriprise Financial Inc. (1.98%) and Acadian Asset Management LLC (1.82%). Insiders that own company stock include Richard A Edlin and Scott Tarriff. View institutional ownership trends .

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Eagle Pharmaceuticals Stock Price, News & Analysis (NASDAQ:EGRX)

$5.95

+0.10 (+1.71%)

(As of 12/1/2023 ET)

Compare

Today's Range: $5.62
▼
$6.05
50-Day Range: $5.68
▼
$15.77
52-Week Range: $5.53
▼
$35.93

Volume: 323,828 shs
Average Volume: 219,535 shs
Market Capitalization: $77.29 million

P/E Ratio: 5.04
Dividend Yield: N/A
Price Target: $17.00

Eagle Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Sell
1.00 Rating Score
Upside/Downside: 185.7% Upside
$17.00 Price Target
Short Interest: Bearish
5.24% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.29
Upright™ Environmental Score
News Sentiment: 0.07
Based on 13 Articles This Week
Insider Trading: Selling Shares
$295,836 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

255th out of 951 stocks

Pharmaceutical Preparations Industry

105th out of 439 stocks

2.5

Analyst's Opinion

Consensus Rating
Eagle Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Eagle Pharmaceuticals has a forecasted upside of 185.7% from its current price of $5.95.
Amount of Analyst Coverage
Eagle Pharmaceuticals has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.24% of the float of Eagle Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Eagle Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Eagle Pharmaceuticals has recently decreased by 3.72%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Eagle Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eagle Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eagle Pharmaceuticals has received a 53.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Bendamustine", "Dantrolene", and "Pemetrexed" products. See details.
Environmental Sustainability
The Environmental Impact score for Eagle Pharmaceuticals is -2.29.

2.3

News and Social Media Coverage

News Sentiment
Eagle Pharmaceuticals has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Eagle Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for EGRX on MarketBeat in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eagle Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $295,836.00 in company stock.
Percentage Held by Insiders
28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.87% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Eagle Pharmaceuticals is 5.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.86.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eagle Pharmaceuticals is 5.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 98.74.
Price to Book Value per Share Ratio
Eagle Pharmaceuticals has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

EGRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EGRX Stock News Headlines

December 1, 2023 | markets.businessinsider.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Eagle Pharmaceuticals, Inc. - EGRX

December 1, 2023 | benzinga.com

Eagle Pharmaceuticals (EGRX) Shares Crash After CEO Tarriff Resigns and Disclosing Non-Compliance with Nasdaq - Hagens Berman

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 30, 2023 | benzinga.com

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Eagle Pharmaceuticals, Inc. (EGRX)

November 30, 2023 | benzinga.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors

November 30, 2023 | businesswire.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors

November 29, 2023 | tmcnet.com

The Law Offices of Frank R. Cruz Announces Investigation of Eagle Pharmaceuticals, Inc. (EGRX) on Behalf of Investors

November 29, 2023 | benzinga.com

Why Is Eagle Pharmaceuticals Stock Trading Lower Today?

December 2, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 29, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Eagle Pharmaceuticals's earnings

November 29, 2023 | finance.yahoo.com

Eagle Pharmaceuticals Announces Management Change

November 29, 2023 | finance.yahoo.com

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

November 27, 2023 | finance.yahoo.com

Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

November 13, 2023 | benzinga.com

Eagle Pharmaceuticals's Earnings: A Preview

November 10, 2023 | finance.yahoo.com

Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

November 8, 2023 | finance.yahoo.com

Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023

November 7, 2023 | morningstar.com

Eagle Pharmaceuticals Inc EGRX

October 24, 2023 | finanznachrichten.de

Eagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Granted Patent for PEMFEXY

October 24, 2023 | baystreet.ca

Eagle Flies on Patent News

October 23, 2023 | finanznachrichten.de

Eagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS from CMS

October 23, 2023 | markets.businessinsider.com

A Bird's Eye View Of Eagle Pharma

October 13, 2023 | finance.yahoo.com

Implied Volatility Surging for Eagle Pharmaceuticals (EGRX) Stock Options

October 12, 2023 | finance.yahoo.com

Shareholders in Eagle Pharmaceuticals (NASDAQ:EGRX) are in the red if they invested five years ago

October 4, 2023 | finance.yahoo.com

Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting

September 19, 2023 | finance.yahoo.com

Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023

August 30, 2023 | finance.yahoo.com

Eagle Pharmaceuticals to Present BYFAVO® (remimazolam) for Injection Abstract at Prestigious Society for Neuroscience in Anesthesiology and Critical Care (SNACC) Conference

August 29, 2023 | finance.yahoo.com

Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114, an Estrogen Receptor Antagonist Used in the Treatment of Metastatic Breast Cancer in Post-Menopausal Women

See More Headlines

Receive EGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 12/02/2023
Next Earnings (Estimated): 12/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:EGRX
CUSIP: N/A
CIK: 827871
Web: www.eagleus.com
Phone: (201) 326-5300
Fax: N/A
Employees: 134
Year Founded: 2007

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $17.00
Low Stock Price Target: $17.00
Potential Upside/Downside: +185.7%
Consensus Rating: Sell
Rating Score (0-4): 1.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.18
Trailing P/E Ratio: 5.04
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $35.64 million
Net Margins: 6.04%
Pretax Margin: 11.33%
Return on Equity: 6.48%
Return on Assets: 3.86%

Debt

Debt-to-Equity Ratio: 0.25
Current Ratio: 2.16
Quick Ratio: 1.67

Sales & Book Value

Annual Sales: $316.61 million
Price / Sales: 0.24
Cash Flow: $3.86 per share
Price / Cash Flow: 1.54
Book Value: $17.94 per share
Price / Book: 0.33

Miscellaneous

Outstanding Shares: 12,990,000
Free Float: 9,234,000
Market Cap: $77.29 million
Optionable: Optionable
Beta: 0.56

Social Links

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Scott L. Tarriff (Age 63)
Founder, President, CEO & Director
Comp: $1.51M
Mr. Brian Joseph Cahill (Age 54)
Chief Financial Officer
Comp: $606.06k
Mr. Ryan Debski
Executive VP, General Counsel & Chief Compliance Officer
Mr. Daniel O'Connor (Age 43)
Executive VP, Chief Strategy Officer & Head of Corporate Development
Dr. Valentin R. Curt M.D.
Senior Vice President of Clinical Drug Development
Dr. Gaozhong Zhu Ph.D.
Senior Vice President of Pharmaceutical Development
Ms. Debra M. Hussain
Senior VP & Head of Commercial
Mr. Reed McClung
Executive Vice President of Oncology Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EGRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Eagle Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" EGRX shares.
View EGRX analyst ratings or view top-rated stocks.
What is Eagle Pharmaceuticals' stock price target for 2024?: 1 brokerages have issued 12 month price objectives for Eagle Pharmaceuticals' shares. Their EGRX share price targets range from $17.00 to $17.00. On average, they predict the company's share price to reach $17.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price.
View analysts price targets for EGRX or view top-rated stocks among Wall Street analysts.
How have EGRX shares performed in 2023?: Eagle Pharmaceuticals' stock was trading at $29.23 at the start of the year. Since then, EGRX shares have decreased by 79.6% and is now trading at $5.95.
View the best growth stocks for 2023 here.
When is Eagle Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023.
View our EGRX earnings forecast.
How were Eagle Pharmaceuticals' earnings last quarter?: Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to the consensus estimate of $46.70 million. Eagle Pharmaceuticals had a trailing twelve-month return on equity of 6.48% and a net margin of 6.04%. During the same quarter in the previous year, the business earned $0.51 earnings per share.

What guidance has Eagle Pharmaceuticals issued on next quarter's earnings?: Eagle Pharmaceuticals issued an update on its FY 2023 earnings guidance on Friday, October, 6th. The company provided earnings per share (EPS) guidance of $4.40-$4.70 for the period, compared to the consensus estimate of $4.58. The company issued revenue guidance of -.
What other stocks do shareholders of Eagle Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Schnitzer Steel Industries (RDUS), bluebird bio (BLUE), Clovis Oncology (CLVS), GW Pharmaceuticals (GWPH) and Incyte (INCY).
Who are Eagle Pharmaceuticals' major shareholders?: Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Brandes Investment Partners LP (8.73%), Adage Capital Partners GP L.L.C. (3.85%), AQR Capital Management LLC (2.18%), Smith Graham & Co. Investment Advisors LP (2.10%), Ameriprise Financial Inc. (1.98%) and Acadian Asset Management LLC (1.82%). Insiders that own company stock include Richard A Edlin and Scott Tarriff.
View institutional ownership trends.
How do I buy shares of Eagle Pharmaceuticals?: Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:EGRX) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial